Literature DB >> 26806320

Lung cancer: Resolving resistance to ALK-targeted therapy.

Lisa Hutchinson.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26806320     DOI: 10.1038/nrclinonc.2016.8

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN: 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  1 in total

1.  Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.

Authors:  Ted W Johnson; Jeffrey A Engelman; Alice T Shaw; Luc Friboulet; Ignaty Leshchiner; Justin F Gainor; Simon Bergqvist; Alexei Brooun; Benjamin J Burke; Ya-Li Deng; Wei Liu; Leila Dardaei; Rosa L Frias; Kate R Schultz; Jennifer Logan; Leonard P James; Tod Smeal; Sergei Timofeevski; Ryohei Katayama; A John Iafrate; Long Le; Michele McTigue; Gad Getz
Journal:  N Engl J Med       Date:  2015-12-23       Impact factor: 91.245

  1 in total
  1 in total

1.  #2714, a novel active inhibitor with potent G2/M phase arrest and antitumor efficacy in preclinical models.

Authors:  Wen-Jie Lu; Wen Peng; Qian-Qian Sun; Yong-Huai Li; Bo Chen; Luo-Ting Yu; You-Zhi Xu; Si-Ying Wang; Ying-Lan Zhao
Journal:  Cell Death Discov       Date:  2018-02-14
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.